SCHEMBL12411167

SCHEMBL12411167

CC(C)(C)OC(=O)N1CCC=C1CCCCCCO

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.37
CYP4F2 P78329 2/20 0.36
CYP4A11 Q02928 2/20 0.36
NR1H2 P55055 2/20 0.34
ESRRB O95718 1/20 0.34
ESR1 P03372 1/20 0.34
ESRRA P11474 1/20 0.34
ESRRG P62508 1/20 0.34
HDAC1 Q13547 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32
KDM1A O60341 1/20 0.32
CTSK P43235 1/20 0.32
USP2 O75604 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
ALDH1A1 P00352 2/20 0.31
GPR119 Q8TDV5 2/20 0.31
CHRM2 P08172 1/20 0.31
CHRM4 P08173 1/20 0.31
CHRM5 P08912 1/20 0.31
CHRM1 P11229 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2070705 0.83 HDAC1 (0.38) NR1H2HDAC1HDAC6KDM1ACTSK
SCHEMBL21915012 0.77 KDM1A (0.37) NR1H2HDAC1HDAC6KDM1ACTSK
SCHEMBL14112126 0.71 USP2 (0.40) NR1H2KDM1ACTSKUSP2SMN1; SMN2
SCHEMBL12661063 0.70 STS (0.33) NR1H2HDAC1HDAC6KDM1AALDH1A1
SCHEMBL5639524 0.69 DHODH (0.58) NR1H2HDAC1HDAC6GPR119CHRM4
SCHEMBL13588590 0.69 GPR119 (0.38) NR1H2KDM1ACTSKUSP2SMN1; SMN2
SCHEMBL5639439 0.68 MPO (0.53) NR1H2HDAC1HDAC6SMN1; SMN2ALDH1A1
SCHEMBL20481168 0.67 MPO (0.38) CYP4F2CYP4A11NR1H2ALDH1A1GPR119
SCHEMBL23620128 0.67 SCN5A (0.38) HDAC1HDAC6KDM1AUSP2SMN1; SMN2
SCHEMBL29877791 0.67 ESR2 (0.36) NR1H2ESRRBESR1ESRRAESRRG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110166170-A1 SYNTHESIS OF AVRAINVILLAMIDE, STEPHACIDIN B, AND ANALOGUES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2011-07-07 US disclosed
US-7902196-B2 Synthesis of avrainvillamide, strephacidin B, and analogues thereof PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2011-03-08 US disclosed
US-20090143581-A1 SYNTHESIS OF AVRAINVILLAMIDE, STREPHACIDIN B, AND ANALOGUES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166170-A1 SYNTHESIS OF AVRAINVILLAMIDE, STEPHACIDIN B, AND ANALOGUES THEREOF MDN1, VASP, ATRIP TDP1 1254/4885CYP4F2 4660/4885CYP4A11 3894/4885
US-20090143581-A1 SYNTHESIS OF AVRAINVILLAMIDE, STREPHACIDIN B, AND ANALOGUES THEREOF MDN1, BIRC3, STAMBP TDP1 963/4885CYP4F2 4774/4885CYP4A11 4423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.